Inventiva selected to present the results of its NATIVE Phase IIb clinical trial with lanifibranor in NASH during a plenary session at The Liver Meeting Digital Experience™ 2020
Daix (France), October 5, 2020 – Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH), mucopolysaccharidoses (MPS) and other diseases with significant unmet medical need, today announced that it has been selected to present the results from its 24-week Phase IIb trial evaluating lanifibranor for the treatment of NASH in an oral plenary presentation at The Liver Meeting Digital Experience™ 2020, which will be held virtually November 13-16, 2020.
Entitled "The panPPAR agonist lanifibranor induces both resolution of NASH and regression of fibrosis after 24 weeks of treatment in non-cirrhotic NASH: results of the NATIVE Phase IIb trial", the abstract will be presented by Prof. Sven Francque, M.D., Ph.D. from Antwerp University Hospital and co-principal investigator of the trial.
During this trial, lanifibranor met the primary endpoint with a statistically significant reduction of the Steatosis Activity Fibrosis score (SAF), which combines assessments of hepatocellular inflammation and ballooning, with no worsening of fibrosis in the Intention To Treat (ITT1) and Per Protocol populations (PP2). In particular, lanifibranor achieved statistically significant effects on NASH resolution with no worsening of fibrosis and improvement of fibrosis with no worsening of NASH, the US Food and Drug Administration (FDA) and European Medicine Agency (EMA) primary endpoints relevant for seeking accelerated approval during future Phase III clinical development.
Oral presentation details
Publication Number: 0012
Session Title: Plenary: Clinical and Outcomes Discoveries
Presentation Type: Oral presentation, Plenary Session
Presenting Author: Sven Francque, M.D., Ph.D. from Antwerp University Hospital
Session Broadcast Date and Time: Sunday, November 15, 2020, 9:00 AM (Eastern Time)
Lanifibranor, Inventiva’s lead product candidate, is an orally-available small molecule that acts to induce anti-fibrotic, anti-inflammatory and beneficial vascular and metabolic changes in the body by activating all three peroxisome proliferator‑activated receptor (PPAR) isoforms, which are well‑characterized nuclear receptor proteins that regulate gene expression. Lanifibranor is a PPAR agonist that is designed to target all three PPAR isoforms in a moderately potent manner, with a well‑balanced activation of PPARα and PPARδ, and a partial activation of PPARγ. While there are other PPAR agonists that target only one or two PPAR isoforms for activation, lanifibranor is the only pan‑PPAR agonist in clinical development. Inventiva believes that lanifibranor’s moderate and balanced pan‑PPAR binding profile contributes to the favorable tolerability profile that has been observed in clinical trials and pre‑clinical studies to date.
About the NATIVE Phase IIb trial
The NATIVE (NAsh Trial to Validate IVA337 Efficacy) clinical trial is a 24-week randomized, double-blind, placebo-controlled Phase IIb clinical trial evaluating lanifibranor for the treatment of patients with NASH. The main purpose of the trial is to assess the efficacy of lanifibranor in improving liver inflammation and ballooning, the two histological markers included in the definition of the regulatory endpoint of NASH resolution. To be considered for inclusion, patients were required to have: a diagnosis of NASH confirmed by liver biopsy; a cumulative score of inflammation and ballooning (as measured using the SAF scoring system) of three or four out of four, indicating the presence of moderate to severe inflammation and ballooning; a steatosis score greater than or equal to one, indicating the presence of moderate to severe steatosis; and a fibrosis score less than four, indicating the absence of cirrhosis. The primary endpoint of the trial is a reduction in the combined inflammation and ballooning score of two points compared to baseline, with no worsening fibrosis, as measured by the SAF score. Secondary endpoints include NASH resolution, improvements in each of the steatosis, inflammation, ballooning and fibrosis scores from baseline as measured using the SAF score, improvements in various other fibrosis measures, improvements in several metabolic markers, improvements in steatosis, inflammation and ballooning as measured using the NAS score (NAFLD activity score), and safety.
The trial randomized 247 patients with NASH in 71 sites in Australia, Canada, Europe, Mauritius and the United States.
Inventiva is a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of NASH, MPS and other diseases with significant unmet medical need.
Leveraging its expertise and experience in the domain of compounds targeting nuclear receptors, transcription factors and epigenetic modulation, Inventiva is currently advancing two clinical candidates, as well as a deep pipeline of earlier stage programs.
Lanifibranor, its lead product candidate, is being developed for the treatment of patients with NASH, a common and progressive chronic liver disease for which there are currently no approved therapies. Inventiva recently announced positive topline data from its Phase IIb clinical trial evaluating lanifibranor for the treatment of patients with NASH.
Inventiva is also developing odiparcil, a second clinical stage asset, for the treatment of patients with subtypes of MPS, a group of rare genetic disorders. A Phase I/II clinical trial in children with MPS VI is currently under preparation following the release of positive results of the Phase IIa clinical trial in adult MPS VI patients at the end of 2019.
In parallel, Inventiva is in the process of selecting an oncology development candidate for its Hippo signalling pathway program. Furthermore, the Company has established a strategic collaboration with AbbVie in the area of autoimmune diseases. AbbVie has started the clinical development of ABBV‑157, a drug candidate for the treatment of moderate to severe psoriasis resulting from its collaboration with Inventiva. This collaboration enables Inventiva to receive milestone payments upon the achievement of pre-clinical, clinical, regulatory and commercial milestones, in addition to royalties on any approved products resulting from the collaboration.
The Company has a scientific team of approximately 70 people with deep expertise in the fields of biology, medicinal and computational chemistry, pharmacokinetics and pharmacology, as well as in clinical development. It also owns an extensive library of approximately 240,000 pharmacologically relevant molecules, approximately 60% of which are proprietary, as well as a wholly‑owned research and development facility.
Inventiva is a public company listed on compartment C of the regulated market of Euronext Paris (Euronext: IVA – ISIN: FR0013233012) and on the Nasdaq Global Market in the United States (ticker: IVA). www.inventivapharma.com
Chairman & CEO
+33 3 80 44 75 00
Yannick Tetzlaff / Tristan Roquet Montegon /
+33 1 53 96 83 83
Westwicke, an ICR Company
Patricia L. Bank
+1 415 513 1284
This press release contains forward-looking statements, forecasts and estimates with respect to Inventiva’s clinical trials, clinical trial data releases, clinical development plans and anticipated future activities of Inventiva. Certain of these statements, forecasts and estimates can be recognized by the use of words such as, without limitation, “believes”, “anticipates”, “expects”, “intends”, “plans”, “seeks”, “estimates”, “may”, “will” and “continue” and similar expressions. Such statements are not historical facts but rather are statements of future expectations and other forward-looking statements that are based on management's beliefs. These statements reflect such views and assumptions prevailing as of the date of the statements and involve known and unknown risks and uncertainties that could cause future results, performance or future events to differ materially from those expressed or implied in such statements. Actual events are difficult to predict and may depend upon factors that are beyond Inventiva's control. There can be no guarantees with respect to pipeline product candidates that the clinical trial results will be available on their anticipated timeline, that future clinical trials will be initiated as anticipated, or that candidates will receive the necessary regulatory approvals. Actual results may turn out to be materially different from the anticipated future results, performance or achievements expressed or implied by such statements, forecasts and estimates, due to a number of factors, including that Inventiva has incurred significant losses since inception, Inventiva has a limited operating history and has never generated any revenue from product sales, Inventiva will require additional capital to finance its operations, Inventiva's future success is dependent on the successful clinical development, regulatory approval and subsequent commercialization of current and any future product candidates, preclinical studies or earlier clinical trials are not necessarily predictive of future results and the results of Inventiva's clinical trials may not support Inventiva's product candidate claims, Inventiva may encounter substantial delays in its clinical trials or Inventiva may fail to demonstrate safety and efficacy to the satisfaction of applicable regulatory authorities, enrollment and retention of patients in clinical trials is an expensive and time-consuming process and could be made more difficult or rendered impossible by multiple factors outside Inventiva's control, Inventiva's product candidates may cause undesirable side effects or have other properties that could delay or prevent their regulatory approval, or limit their commercial potential, Inventiva faces substantial competition and Inventiva’s business, preclinical studies and clinical development programs and timelines, its financial condition and results of operations could be materially and adversely affected by the current COVID-19 pandemic. Given these risks and uncertainties, no representations are made as to the accuracy or fairness of such forward-looking statements, forecasts and estimates. Furthermore, forward-looking statements, forecasts and estimates only speak as of the date of this press release.Readers are cautioned not to place undue reliance on any of these forward-looking statements.
Please refer to the Universal Registration Document filed with the Autorité des Marchés Financiers on June 19, 2020 under n° D.20-0551 and its amendment filed on July 10, 2020 under n° D. 20-0551-A01 as well as the half-year financial report on June 30, 2020 for additional information in relation to such factors, risks and uncertainties.
Except as required by law, Inventiva has no intention and is under no obligation to update or review the forward-looking statements referred to above. Consequently, Inventiva accepts no liability for any consequences arising from the use of any of the above statements.
1 ITT: includes all patients randomized in the trial.
2 PP: includes all patients with paired biopsies and without deviation impacting efficacy assessment.
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire
Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire
Touax: Success of the partial buyback of the Undated Deeply Subordinated Bond27.11.2020 17:45:00 CET | Press release
PRESS RELEASE Paris, November 27, 2020 – 5.45 p.m. YOUR OPERATIONAL LEASING SOLUTION FOR SUSTAINABLE TRANSPORTATION Success of the partial buyback of the Undated Deeply Subordinated Bond Touax SCA announces today that it has bought back and canceled part of the Undated Deeply Subordinated Bond issued in August 2013, November 2013 and May 2014, for a nominal amount of 24.2 million euros. The outstanding amount of the bonds stands at 26.6 million euros. This operation will enable to optimize the capital structure of the Group and to lower the related costs. Fabrice and Raphaël Walewski, managing partners of Touax Group commented: “The strategic refocusing initiated since 2018 around the long-term rental business of environmentally-friendly transport equipment has allowed a return to growth and profit over the first half of 2020. The capital increase of Touax Rail for 81.9 million euros achieved at the end of September 2020 significantly strengthened the capital of the Rail division and t
CONDITIONS FOR RIKSBANK REVERSED AUCTIONS SEK MUNICIPAL BONDS27.11.2020 16:20:00 CET | Press release
Anbudsförfarande kommuner och regioner, 2020-12-01BondsFixed rate notes issued in SEK by Municipalities or Regions with maturity in: 2025 The following issuers are accepted for delivery: Göteborgs Stad Jönköpings Kommun Malmö Stad Nacka Kommun Region Skåne Stockholms Stad Region Stockholm Vellinge Kommun Västerås Stad Delivery may not be made in Bonds purchased by the Counterparty from the issuer less than one week prior to the date for announcing the Specific terms, i.e. the purchase may not have been made after: 2020-11-20BidsBids are made to tel 08-696 69 70 and confirmed in writing by a filled-in Bid form by e-mail to EOL@riksbank.se Bid date2020-12-01Bid times10.00-11.00 (CET/CEST) on the Bid dateRequested volume (corresponding nominal amount)SEK 750 +/- 750 millionHighest permitted bid volume (corresponding nominal amount)The total bid volume from one Counterparty for the two Credit rating classes may not exceed SEK 1 000 million. No bid may contain Bonds exceeding SEK 750 millio
CONDITIONS FOR PURCHASES OF CORPORATE BONDS27.11.2020 16:20:00 CET | Press release
Bid procedure, 2020-12-02BondsBonds issued in SEK by Swedish non-financial undertakings. The following bonds are eligible for delivery: VASAKRONAN AB: XS1941844174, 2022-02-11 VASAKRONAN AB: XS2051470552, 2024-09-11 HEMSO FASTIGHETS AB: XS1876163103, 2022-03-07 HEMSO FASTIGHETS AB: XS1938445530, 2021-10-22 VOLVO TREASURY AB: XS2153414292, 2022-12-08 VOLVO TREASURY AB: XS2018763461, 2021-06-28 HUSQVARNA AB: SE0009664543, 2022-03-01 HUSQVARNA AB: SE0010869669, 2023-02-14 AB INDUSTRIVARDEN: SE0011869668, 2022-02-28 AB INDUSTRIVARDEN: SE0012676724, 2023-02-20 Delivery of a Bond may not occur if the Counterparty has purchased the Bond from the issuer more recently than one month prior to the date of announcement of the Special terms, that is, the purchase may not have taken place after: 2020-11-02Bid date2020-12-02Bid times10.00-11.00 (CET/CEST) on the Bid dateRequested volume (corresponding nominal amount)XS1941844174: 30 mln SEK +/-30 mln SEK XS2051470552: 30 mln SEK +/-30 mln SEK XS18761
CONDITIONS FOR RIKSBANK REVERSED AUCTIONS SEK COVERED BONDS27.11.2020 16:20:00 CET | Press release
Bid procedure, 2020-12-03BondsSTADSHYPOTEK AB: 1590, SE0012676690, 2025-09-03 SWEDBANK HYPOTEK AB: 194, SE0012142206, 2024-09-18 NORDEA HYPOTEK AB: 5535, SE0013358413, 2025-09-17 SKANDINAVISKA ENSKILDA: 580, SE0013101722, 2025-12-17 LANSFORSAKRINGAR HYPOTEK: 518, SE0011309244, 2025-09-17 DANSKE HYPOTEK AB: 2512, SE0013877214, 2025-12-17 SWEDISH COVERED BOND: 146, SE0013381571, 2025-06-11 Bid date2020-12-03Bid times09.00-10.00 (CET/CEST) on the Bid dateRequested volume (corresponding nominal amount)1590: 1200 mln SEK +/-600 mln SEK 194: 1000 mln SEK +/-500 mln SEK 5535: 1000 mln SEK +/-500 mln SEK 580: 800 mln SEK +/-400 mln SEK 518: 600 mln SEK +/-300 mln SEK 2512: 300 mln SEK +/-150 mln SEK 146: 600 mln SEK +/-300 mln SEK Maximum 5500 mln in totalHighest permitted bid volume (corresponding nominal amount)1590: 1200 mln SEK per bid 194: 1000 mln SEK per bid 5535: 1000 mln SEK per bid 580: 800 mln SEK per bid 518: 600 mln SEK per bid 2512: 300 mln SEK per bid 146: 600 mln SEK per bid Lo
CONDITIONS FOR RIKSBANK REVERSED AUCTIONS SEK GOVERNMENT BONDS27.11.2020 16:20:00 CET | Press release
Bid procedure, 2020-12-04BondsSWEDEN I/L BOND: 3108, SE0004211084, 2022-06-01 SWEDEN I/L BOND: 3109, SE0005703550, 2025-06-01 Bid date2020-12-04Bid times09.00-10.00 (CET/CEST) on the Bid dateRequested volume (corresponding nominal amount)3108: 500 mln SEK +/-250 mln SEK 3109: 500 mln SEK +/-250 mln SEK Maximum 1000 mln in totalHighest permitted bid volume (corresponding nominal amount)3108: 500 mln SEK per bid 3109: 500 mln SEK per bid Lowest permitted bid volume (corresponding nominal amount)SEK 50 million per bidExpected allocation timeNo later than 10.10 (CET/CEST) on the Bid dateDelivery and payment date2020-12-08Delivery of bondsTo the Riksbank's account in Euroclear Sweden AB's securities settlement system 1 4948 6383 Stockholm, 2020-11-27 This is a translation of the special terms and conditions published on www.riksbank.se. In the case of any inconsistency between the English translation and the Swedish language version, the Swedish language version shall prevail. Complete term
Greenfield cement project in Ethiopia is effective27.11.2020 15:45:28 CET | Press release
Company Announcement No. 21 -2020, 3 November 2020 The previously announced signed contract for engineering, procurement and supervision on a cement plant in Ethiopia (Company Announcement No. 1-2019 on 24 January 2019) with Abay Industrial Development Share Company, is now effective. Located near the city of Dejen in Ethiopia, the new greenfield plant will play an important role for the development of local infrastructure. Once fully operational the plant will have a capacity of 5,000 tonnes per day and creating more than 300 new jobs in the area. The contract is valued at around EUR 100 million. The order includes design and engineering, full equipment supply, automation systems, installation and commissioning as well as training and extended supervision. Key deliveries are expected to commence towards the end of 2021. The majority of revenue from this project is expected in the subsequent years. “We are happy to see the contract now in effect,” said Carsten Riisberg Lund, President,